Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: A SEER-medicare analysis

Sikander Ailawadhi, Ryan D. Frank, Pooja Advani, Abhisek Swaika, M'hamed Temkit, Richa Menghani, Mayank Sharma, Zahara Meghji, Shumail Paulus, Nandita D Khera, Shahrukh K. Hashmi, Aneel Paulus, Tanya S. Kakar, David O. Hodge, Dorin T. Colibaseanu, Michael R. Vizzini, Vivek Roy, Gerardo Colon-Otero, Asher A Chanan Khan

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Outcomes have improved considerably in multiple myeloma (MM), but disparities among racial-ethnic groups exist. Differences in utilization of novel therapeutics are likely contributing factors. We explored such differences from the SEER-Medicare database. A utilization analysis of lenalidomide, thalidomide, bortezomib, and stem cell transplant (SCT) was performed for patients diagnosed with MM between 2007 and 2009, including use over time, use by race, time-dependent trends for each racial subgroup, and survival analysis. A total of 5338 MM patients were included with median 2.4-year follow-up. Within the first year of MM diagnosis, utilization of lenalidomide, bortezomib, SCT, and more than one novel agent increased over time while utilization of thalidomide decreased. There was significantly lower utilization of lenalidomide among African-Americans (P < 0.01), higher thalidomide use among Hispanics and Asians (P < 0.01), and lower bortezomib use among Asians (P < 0.01). Hispanics had the highest median number of days to first dose of bortezomib (P = 0.02) and the lowest utilization of SCT (P < 0.01). Hispanics and Asians were the only groups without notable increases in lenalidomide and bortezomib use, respectively. SCT utilization increased over time for all except African-Americans. SCT use within the first year after diagnosis was associated with better overall survival (HR 0.52; 95% CI: 0.4-0.68), while bortezomib use was associated with inferior survival (HR 1.14; 95% CI 1.02-1.28). We noted considerable variability in MM therapeutics utilization with seeming inequity for racial-ethnic minorities. These trends should be considered to eliminate drug access and utilization disparities and achieve equitable benefit of therapeutic advances across all races.

Original languageEnglish (US)
JournalCancer Medicine
DOIs
StateAccepted/In press - 2017

Fingerprint

Medicare
Multiple Myeloma
Stem Cells
Thalidomide
Transplants
Hispanic Americans
African Americans
Therapeutics
Drug Utilization
Survival
Survival Analysis
Ethnic Groups
Bortezomib
Databases
lenalidomide

Keywords

  • Cancer management

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Racial disparity in utilization of therapeutic modalities among multiple myeloma patients : A SEER-medicare analysis. / Ailawadhi, Sikander; Frank, Ryan D.; Advani, Pooja; Swaika, Abhisek; Temkit, M'hamed; Menghani, Richa; Sharma, Mayank; Meghji, Zahara; Paulus, Shumail; Khera, Nandita D; Hashmi, Shahrukh K.; Paulus, Aneel; Kakar, Tanya S.; Hodge, David O.; Colibaseanu, Dorin T.; Vizzini, Michael R.; Roy, Vivek; Colon-Otero, Gerardo; Chanan Khan, Asher A.

In: Cancer Medicine, 2017.

Research output: Contribution to journalArticle

Ailawadhi, S, Frank, RD, Advani, P, Swaika, A, Temkit, M, Menghani, R, Sharma, M, Meghji, Z, Paulus, S, Khera, ND, Hashmi, SK, Paulus, A, Kakar, TS, Hodge, DO, Colibaseanu, DT, Vizzini, MR, Roy, V, Colon-Otero, G & Chanan Khan, AA 2017, 'Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: A SEER-medicare analysis', Cancer Medicine. https://doi.org/10.1002/cam4.1246
Ailawadhi, Sikander ; Frank, Ryan D. ; Advani, Pooja ; Swaika, Abhisek ; Temkit, M'hamed ; Menghani, Richa ; Sharma, Mayank ; Meghji, Zahara ; Paulus, Shumail ; Khera, Nandita D ; Hashmi, Shahrukh K. ; Paulus, Aneel ; Kakar, Tanya S. ; Hodge, David O. ; Colibaseanu, Dorin T. ; Vizzini, Michael R. ; Roy, Vivek ; Colon-Otero, Gerardo ; Chanan Khan, Asher A. / Racial disparity in utilization of therapeutic modalities among multiple myeloma patients : A SEER-medicare analysis. In: Cancer Medicine. 2017.
@article{28710c4719a9427b9938ca61b7d1d7f2,
title = "Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: A SEER-medicare analysis",
abstract = "Outcomes have improved considerably in multiple myeloma (MM), but disparities among racial-ethnic groups exist. Differences in utilization of novel therapeutics are likely contributing factors. We explored such differences from the SEER-Medicare database. A utilization analysis of lenalidomide, thalidomide, bortezomib, and stem cell transplant (SCT) was performed for patients diagnosed with MM between 2007 and 2009, including use over time, use by race, time-dependent trends for each racial subgroup, and survival analysis. A total of 5338 MM patients were included with median 2.4-year follow-up. Within the first year of MM diagnosis, utilization of lenalidomide, bortezomib, SCT, and more than one novel agent increased over time while utilization of thalidomide decreased. There was significantly lower utilization of lenalidomide among African-Americans (P < 0.01), higher thalidomide use among Hispanics and Asians (P < 0.01), and lower bortezomib use among Asians (P < 0.01). Hispanics had the highest median number of days to first dose of bortezomib (P = 0.02) and the lowest utilization of SCT (P < 0.01). Hispanics and Asians were the only groups without notable increases in lenalidomide and bortezomib use, respectively. SCT utilization increased over time for all except African-Americans. SCT use within the first year after diagnosis was associated with better overall survival (HR 0.52; 95{\%} CI: 0.4-0.68), while bortezomib use was associated with inferior survival (HR 1.14; 95{\%} CI 1.02-1.28). We noted considerable variability in MM therapeutics utilization with seeming inequity for racial-ethnic minorities. These trends should be considered to eliminate drug access and utilization disparities and achieve equitable benefit of therapeutic advances across all races.",
keywords = "Cancer management",
author = "Sikander Ailawadhi and Frank, {Ryan D.} and Pooja Advani and Abhisek Swaika and M'hamed Temkit and Richa Menghani and Mayank Sharma and Zahara Meghji and Shumail Paulus and Khera, {Nandita D} and Hashmi, {Shahrukh K.} and Aneel Paulus and Kakar, {Tanya S.} and Hodge, {David O.} and Colibaseanu, {Dorin T.} and Vizzini, {Michael R.} and Vivek Roy and Gerardo Colon-Otero and {Chanan Khan}, {Asher A}",
year = "2017",
doi = "10.1002/cam4.1246",
language = "English (US)",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - Racial disparity in utilization of therapeutic modalities among multiple myeloma patients

T2 - A SEER-medicare analysis

AU - Ailawadhi, Sikander

AU - Frank, Ryan D.

AU - Advani, Pooja

AU - Swaika, Abhisek

AU - Temkit, M'hamed

AU - Menghani, Richa

AU - Sharma, Mayank

AU - Meghji, Zahara

AU - Paulus, Shumail

AU - Khera, Nandita D

AU - Hashmi, Shahrukh K.

AU - Paulus, Aneel

AU - Kakar, Tanya S.

AU - Hodge, David O.

AU - Colibaseanu, Dorin T.

AU - Vizzini, Michael R.

AU - Roy, Vivek

AU - Colon-Otero, Gerardo

AU - Chanan Khan, Asher A

PY - 2017

Y1 - 2017

N2 - Outcomes have improved considerably in multiple myeloma (MM), but disparities among racial-ethnic groups exist. Differences in utilization of novel therapeutics are likely contributing factors. We explored such differences from the SEER-Medicare database. A utilization analysis of lenalidomide, thalidomide, bortezomib, and stem cell transplant (SCT) was performed for patients diagnosed with MM between 2007 and 2009, including use over time, use by race, time-dependent trends for each racial subgroup, and survival analysis. A total of 5338 MM patients were included with median 2.4-year follow-up. Within the first year of MM diagnosis, utilization of lenalidomide, bortezomib, SCT, and more than one novel agent increased over time while utilization of thalidomide decreased. There was significantly lower utilization of lenalidomide among African-Americans (P < 0.01), higher thalidomide use among Hispanics and Asians (P < 0.01), and lower bortezomib use among Asians (P < 0.01). Hispanics had the highest median number of days to first dose of bortezomib (P = 0.02) and the lowest utilization of SCT (P < 0.01). Hispanics and Asians were the only groups without notable increases in lenalidomide and bortezomib use, respectively. SCT utilization increased over time for all except African-Americans. SCT use within the first year after diagnosis was associated with better overall survival (HR 0.52; 95% CI: 0.4-0.68), while bortezomib use was associated with inferior survival (HR 1.14; 95% CI 1.02-1.28). We noted considerable variability in MM therapeutics utilization with seeming inequity for racial-ethnic minorities. These trends should be considered to eliminate drug access and utilization disparities and achieve equitable benefit of therapeutic advances across all races.

AB - Outcomes have improved considerably in multiple myeloma (MM), but disparities among racial-ethnic groups exist. Differences in utilization of novel therapeutics are likely contributing factors. We explored such differences from the SEER-Medicare database. A utilization analysis of lenalidomide, thalidomide, bortezomib, and stem cell transplant (SCT) was performed for patients diagnosed with MM between 2007 and 2009, including use over time, use by race, time-dependent trends for each racial subgroup, and survival analysis. A total of 5338 MM patients were included with median 2.4-year follow-up. Within the first year of MM diagnosis, utilization of lenalidomide, bortezomib, SCT, and more than one novel agent increased over time while utilization of thalidomide decreased. There was significantly lower utilization of lenalidomide among African-Americans (P < 0.01), higher thalidomide use among Hispanics and Asians (P < 0.01), and lower bortezomib use among Asians (P < 0.01). Hispanics had the highest median number of days to first dose of bortezomib (P = 0.02) and the lowest utilization of SCT (P < 0.01). Hispanics and Asians were the only groups without notable increases in lenalidomide and bortezomib use, respectively. SCT utilization increased over time for all except African-Americans. SCT use within the first year after diagnosis was associated with better overall survival (HR 0.52; 95% CI: 0.4-0.68), while bortezomib use was associated with inferior survival (HR 1.14; 95% CI 1.02-1.28). We noted considerable variability in MM therapeutics utilization with seeming inequity for racial-ethnic minorities. These trends should be considered to eliminate drug access and utilization disparities and achieve equitable benefit of therapeutic advances across all races.

KW - Cancer management

UR - http://www.scopus.com/inward/record.url?scp=85032917189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032917189&partnerID=8YFLogxK

U2 - 10.1002/cam4.1246

DO - 10.1002/cam4.1246

M3 - Article

C2 - 29105343

AN - SCOPUS:85032917189

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

ER -